MediLedger: Blockchain-based Pharmaceutical Traceability
Sector: Tertiary sector · Industry: Pharmaceutical sales and services · Organisation: MediLedger · Maturity level: Production
MediLedger is an industry-led blockchain project that improves the traceability and authenticity of pharmaceuticals in the supply chain from manufacturer to dispenser. The system reduces verification time for returned medications from up to 48 hours to less than 400 milliseconds and supports compliance with the Drug Supply Chain Security Act (DSCSA). Since 2019, the network has been commercially operational and was successfully tested in a comprehensive FDA pilot project in 2023.
Documentation status
- Project status: Production
- Evidence: Evidence high
- Editorial review: Ufuk Avci, 15 April 2026
Description
MediLedger is a Hyperledger Fabric-based blockchain platform for DSCSA compliance, developed by Chronicled (San Francisco). The FDA pilot report (available on fda.gov) documents the technical architecture in detail: each medication unit is managed as a non-fungible token; ownership changes via smart contract; zk-SNARKs protect proprietary pricing data.
The DSCSA (Drug Supply Chain Security Act, 2013) mandates phased full serialization and interoperable traceability of all US prescription drugs. Full compliance became mandatory in November 2023. MediLedger architecture: each package receives a serial number; upon shipping, the manufacturer creates a blockchain entry (EPCIS standard); each ownership change (manufacturer→wholesaler→pharmacy) is documented as a smart contract transaction. zk-SNARKs (Zero-Knowledge Succinct Non-Interactive Arguments of Knowledge): compliance checks can be performed without revealing price negotiation or quantity data. Performance test in the FDA pilot: 2,000 transactions per second achieved — sufficient for the US pharmaceutical industry. Ledger Insights was the first media outlet to report extensively on the FDA MediLedger pilot. NCBI/PMC publication: scientific validation of blockchain-based drug traceability.
Perspectives
B2B — organisations perspective
Pharmaceutical manufacturers, wholesalers, and pharmacies can fully automate DSCSA compliance via MediLedger: serialization, chain of ownership, recall management — all blockchain-secured and FDA-auditable.
B2C — consumers perspective
Patients and end consumers indirectly benefit from a safer medication supply through improved traceability and reduced counterfeit protection. Faster verification processes can lead to shorter waiting times in pharmacies.
Employees perspective
Employees in pharmacies and wholesale companies can perform medication verifications in seconds instead of hours and have more time for value-adding activities. Automation reduces repetitive manual checks and minimises human errors in compliance processes.
Benefits
General
- Verification time for returned medications is reduced from up to 48 hours to less than 400 milliseconds.
- The system simplifies chargeback processes and optimises the entire supply chain through automated compliance adherence.
- Blockchain technology provides immutable records and increases transparency in the pharmaceutical supply chain.
B2B — organisations
- Companies achieve cost savings through more efficient system operations and automated DSCSA compliance processes.
Employees
- Employees can complete verification processes significantly faster and have more time for patient-focused activities.
Challenges
General
- Implementation requires comprehensive coordination among all supply chain actors from manufacturers to pharmacies.
- Integration with existing legacy systems and ERP software poses high technical demands on IT infrastructure.
B2B — organisations
- Companies must adapt their existing processes and invest in new barcode scanners and software integrations.
Employees
- Employees need training for the new blockchain-based verification systems and scanner technologies.
Technology foundation
MediLedger uses a decentralised blockchain network specifically developed for the needs of the pharmaceutical industry. Blockchain technology enables the creation of an immutable and transparent record of all medication transactions, thereby verifying product authenticity and preventing counterfeiting.
Implementation examples
MediLedger FDA pilot project 2023
The FDA required a proven practical solution for implementing the DSCSA requirements for medication traceability at the package level. The pilot project was intended to prove that blockchain technology can meet regulatory standards and function in the real pharmaceutical supply chain.
Comprehensive FDA pilot project for DSCSA package-level tracing involving the entire supply chain.
In 2023, MediLedger conducted a comprehensive FDA pilot project testing the requirements of the Drug Supply Chain Security Act for package-level tracing. The project involved manufacturers, wholesalers and dispensers along the entire pharmaceutical supply chain. The tests demonstrated the functionality of the blockchain solution for complete medication traceability and confirmed compliance with regulatory requirements.
The project addressed the challenge of complete medication traceability according to DSCSA regulations and coordination between different supply chain actors. It solved the problem of slow verification processes and demonstrated the practical feasibility of blockchain in regulated environments.
Tags
Supply chain, Traceability, Medications, Compliance, Verification